Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program

Condition(s) studied

Investigational drug(s) / intervention(s)

WGS Diagnostic: Blood take for genetic diagnostic: Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).

Study summary

The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular cause of the disease, suspected genetic cause of the disease without detailed molecular analysis like Whole Exome Sequencing (WES).

The novelty of this study is to integrate genomic health concepts into immediate clinical care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized medicine (Personalized, Predictive, Preventive) integrated into a well-established health care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will be implemented.

The overall goal of this study is to implement, for the first time, Whole Genome Sequencing (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare Disease (RD )and familial cancer syndromes.

Eligibility

Primary outcome measure(s)

• Number of WGS analysis — Day 1
  WGS analysis as a first line diagnostic test for all clinical indications

Trial sites (1)

More University Hospital Tuebingen trials in Germany

Other trials for the same condition